22 July 2020 | News
To date, Antengene has made significant progress with its broad pipeline of six clinical-stage programs and six pre-clinical stage oncology assets
Image credit- shutterstock.com
Chinese startup Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, has announced that it has successfully closed US$97 million in Series C financing.
The financing was led by Fidelity Management & Research Company LLC with additional support from new investors including GL Ventures (an affiliate of Hillhouse Capital), GIC, and a large, reputable long-term investor. Existing investors including Qiming Venture Partners and Boyu Capital also participated.
Proceeds from the Series C financing will be primarily used to fund the continuing clinical development of Antengene's robust pipeline of hematology and oncology therapies, expanding in-house research and development capabilities and strengthening the commercial infrastructures in APAC markets. To date, Antengene has made significant progress with its broad pipeline of six clinical-stage programs and six pre-clinical stage oncology assets.
In addition, the Antengene drug discovery team is focused on the research and pre-clinical development of innovative small molecules, monoclonal and bi-specific antibodies to treat cancer.